Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues

Launched by ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE · Jul 10, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether certain eye drops called prostaglandin analogues, commonly used to treat glaucoma, do more than just lower eye pressure. Specifically, the study wants to find out if these drops can protect important nerve cells in the eye (called retinal ganglion cells) from damage, which could help slow down vision loss over time. Researchers will compare patients using prostaglandin analogue drops with those using other types of eye pressure-lowering drops to see which treatment better protects these nerve cells over three years.

Adults aged 18 and older who have been diagnosed with glaucoma and have been treated with either prostaglandin analogue eye drops or other pressure-lowering drops for at least three years might be eligible. Participants should have regular eye check-ups documented over this time, including tests of eye pressure and vision. If you join the study, your medical records will be reviewed to track how your eye health has changed, but no new treatments will be given as part of the study. This research will help doctors understand if prostaglandin analogue drops should be preferred for long-term glaucoma care to better protect vision.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18+ years
• • Established glaucoma diagnosis (primary open-angle glaucoma, normal tension Glaucoma, pseudoexfoliation glaucoma, pigmentary dispersion glaucoma) in either eye
• • Visual field mean deviation (MD; location-weighted mean difference from average age-corrected visual field sensitivity) of 2 visual fields differing by no more than 3 dB, for a mean deviation of better than -6.0 dB, or by no more than 4 dB, for a mean deviation worse than -6.0 dB, as measured using Humphrey perimetry (or equivalent Haag-Streit / Octopus; in at least one eye; analogous to The United Kingdom Glaucoma Treatment Study)
• • Treatment with either prostaglandin analogues only or another topically applied IOP-lowering compound only for at least 3 years
• • Documented follow-up period of at least 3 years
• • At least 6 patient visits documented over the follow-up period with readings of IOP, visual field, OCT
• • No additional glaucoma intervention apart from laser trabeculoplasty and/or cataract surgery during the observational period
• Exclusion Criteria:
• • Follow-up period \< 3 years
• • Number of patient visits \<6 visits
• • Number of OCT, visual field readings during the observation period \< 6
• • Low compliance/therapy interruption
• • Beginning of combination therapy of prostaglandin analogues and other IOP lowering eye drops during the observation period
• • In case of glaucoma diagnosis in both eyes: different topical IOP-lowering treatment regimes (e.g. prostaglandin analogues in one eye and beta-adrenergic blocking agents in the fellow eye)
• • Additional glaucoma intervention during the observational period other than laser trabeculoplasty and/or cataract surgery